SAN DIEGO, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will host an Investor Day on Thursday, November 16, 2017, from 8:30 a.m. to 10:30 a.m. ET in New York City. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, and Antonio Gualberto, M.D., Ph.D., Chief Medical Officer, will provide a comprehensive overview of the company’s clinical development program for its lead product candidate, tipifarnib, in HRAS mutant head and neck squamous cell carcinoma (HNSCC).
Interested parties may access a live audio webcast and slides of the presentations on the investor section of Kura’s website at www.kuraoncology.com beginning at 8:30 a.m. ET. An archive of the webcast will be available shortly after the event and can be viewed at the same link for a limited time.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
Pete De Spain
Vice President, Investor Relations &
Kura Oncology, Inc.
Robert H. Uhl
Westwicke Partners, LLC